Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381)

Bibliography

• Henikoff S, Matzke MA. Exploring and explaining epigenetic effects. Trends Genet 1997;13:293-5
   PubMed Web of Science ®Google Scholar
• Arrowsmith CH, Bountra C, Fish PV, Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384-400
   PubMed Web of Science ®Google Scholar
• Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009;8:724-32
   PubMed Web of Science ®Google Scholar
• Popovic R, Licht JD. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2012;2:405-13
   PubMed Web of Science ®Google Scholar
• Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011;25:1345-58
   PubMed Web of Science ®Google Scholar
• Mohan M, Lin C, Guest E, Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010;10:721-8
   PubMed Web of Science ®Google Scholar
• Bernt KM, Zhu N, Sinha AU, MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011;20:66-78
   PubMed Web of Science ®Google Scholar
• Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-33
   PubMed Web of Science ®Google Scholar
• Huret JL, Dessen P, Bernheim A. An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners. Leukemia 2001;15:987-9
   PubMed Web of Science ®Google Scholar
• Meyer C, Schneider B, Jakob S, The MLL recombinome of acute leukemias. Leukemia 2006;20:777-84
   PubMed Web of Science ®Google Scholar
• Okada Y, Feng Q, Lin Y, hDOT1L links histone methylation to leukemogenesis. Cell 2005;121:167-78
   PubMed Web of Science ®Google Scholar
• Epizyme, Inc. Substituted purine and 7-deazapurie compounds as modulators of epigenetic enzymes. WO2012075381A1; 2012
   Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011;20:53-65
   PubMed Web of Science ®Google Scholar
• Chen L, Deshpande A, Banka D, Abrogation of MLL-AF10 and CALM-AF10 mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase DOT1L. Leukemia 2012; doi:10.1038/leu.2012.327
   Google Scholar
• Yao Y, Chen P, Diao J, Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc 2011;133:16746-9
   PubMed Web of Science ®Google Scholar
• Basavapathruni A, Jin L, Daigle SR, Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des 2012;80:971-80
   PubMed Web of Science ®Google Scholar
• Anglin JL, Deng L, Yao Y, Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. J Med Chem 2012;55:8066-74
   PubMed Web of Science ®Google Scholar
• Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof. WO082436; 2012
   Google Scholar
• Epizyme, Inc. 7-Deazapurine modulators of histone methyltransferase, and methods of use thereof. WO075500; 2012
   Google Scholar
• Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds. WO075492; 2012
   Google Scholar
• Epizyme, Inc. A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene, U.S. National Institutes of Health. Available from: http://clinicaltrials.gov/show/NCT01684150
   Google Scholar
• Pollock RM, Daigle SR, Therkelsen CA, Preclinical characterization of a potent, selective inhibitor of the protein methyltransferase DOT1L for use in the treatment of MLL-rearranged leukemia. Blood (ASH Annual Meeting Abstracts) 2012;120:2379
   Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011;11:726-34
   PubMed Web of Science ®Google Scholar
• Wagner T, Jung M. New lysine methyltransferase drug targets in cancer. Nat Biotechnol 2012;30:622-3
   PubMed Web of Science ®Google Scholar
• Chemical Abstracts Service, Scifinder. Available from: https://scifinder.cas.org/scifinder/ [Last accessed 12 December 2012]
   Google Scholar
• World Intellectual Property Organization, Patentscope. Available from: http://patentscope.wipo.int/ [Last accessed 12 December 2012]
   Google Scholar
• Cartwright H. GlaxoSmithKline forms US$650 M epigenetics alliance with epizyme. PharmaDeals Rev 2011;2011:7
   Google Scholar
• Flemming A. Deal watch: epizyme-celgene deal signals interest in new class of epigenetic drugs. Nat Rev Drug Discov 2012;11:508
   PubMed Web of Science ®Google Scholar
• Bayer Health Care. Available from: www.bayerpharma.com [Last accessed 6 December 2012]
   Google Scholar
• Lee EQ, Puduvalli VK, Reid JM, Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: north American Brain Tumor Consortium Study 04-03. Clin Cancer Res 2012;18:6032-9
   PubMed Web of Science ®Google Scholar
• Kubo M, Kanaya N, Petrossian K, Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat 2013;37:93-107
   Google Scholar
• Jones SF, Infante JR, Thompson DS, A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 2012;70:471-5
   Google Scholar
• Schoch C, Schnittger S, Klaus M, AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003;102:2395-402
   PubMed Web of Science ®Google Scholar